Older heart disease patients with drug-eluting stents fare better when it comes to heart attacks and mortality rates than patients with bare metal stents, according to a study funded by the federal Health & Human Services dept.’s Agency for Healthcare Research and Quality.
The outcome of the 10-year court battle is still murky, despite the ruling, which failed to determine “the question of who owes what to whom,” according to the journal.
A three-year trial comparing Abbott Laboratories‘ Xience V drug-eluting stent against its Taxus competitor from Boston Scientific Corp. showed that the Abbott device is much more effective three years after implantation.
The news, announced at an American College of Cardiology conference in Orlando, sent the Natick device goliath’s stock into a slight swoon. The Xience product is already outselling the Taxus, and the news promises to accelerate that trend.
March 16 capped off a rough week for Boston Scientific Corp. and its Taxus stent line.
Two days later, the same day the Natick-based device giant settled a patent infringement case filed by a Texas physician, it was slapped with another by a Hong Kong cardiovascular device maker.
Boston Scientific Corp. co-founders John Abele and Peter Nicholas unloaded millions of dollars worth of their stakes in the company in March alone.
It’s part of their effort to salvage the Natick-based medical device leviathan’s stock price, which fell from about $45 per share five years ago to less than $9, according to The Boston Globe.
Add to that the failure of its Taxus Express drug-eluting stent and the disastrous, $27 billion buyout Guidant Corp. (which added $10 billion in debt and thousands of safety recalls in 2006).
Boston Scientific Corp.’s iCross coronary imaging catheter hit the United States market March 19, two days after the company said two of its new drug coated stents should debut in Europe later this year — possibly earlier in non-EU countries.
The Natick medical device colossus said its iCross coronary imaging catheter, designed for use with its intravascular ultrasound iLab imaging system, is now available in the U.S.
Following a less than two-year stint on the board of directors at Boston Scientific Corp., J. Raymond Elliot resigned his seat to start a new, as-yet unspecified venture.
The Natick medical device colossus said March 9 that Elliot would not stand for re-election at the company’s annual shareholders meeting.
Out of the frying pan and into … the skillet?
That’s about the size of it for Boston Scientific Corp., which saw its bond rating raised from negative to stable by Moody’s Investors Service. It’s good news, but there’s still a ways to go.
Moody’s upgraded the Natick-based medical device giant’s U.S. public bond rating March 10 from “Ba2” to “Ba1” and its liquidity rating from “SGL-3” to “SGL-2”, while affirming its corporate credit rating at “Ba1.”
Boston Scientific Corp.‘s Taxus Liberte drug-eluting stent was given regulatory approvals in Japan, clearing the way for its appearance on the Japanese market.
The Natick medical device leviathan said March 3 that its paclitaxel-eluting coronary stent system was approved Jan. 28 by Japan’s Ministry of Health, Labor and Welfare. Reimbursement was granted March 2 by the country’s National Health Insurance System.
About 1,300 medical centers perform cardiac catheterizations in Japan, implanting an estimated 200,000 coronary stents annually, according to Boston Scientific.